{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:04:51Z","timestamp":1784905491837,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007386","name":"Modena Savings Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jbior.2023.100974","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T02:50:06Z","timestamp":1684810206000},"page":"100974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells"],"prefix":"10.1016","volume":"89","author":[{"given":"Salihanur","family":"Darici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather G.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Antolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Barozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5545-9319","authenticated-orcid":false,"given":"Sandra","family":"Marmiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zavatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2023.100974_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18632\/oncotarget.27489","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2023.100974_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fonc.2018.00444","article-title":"Acute myeloid leukemia and the bone marrow niche\u2014take a closer look","volume":"8","author":"Behrmann","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbior.2023.100974_bib3","doi-asserted-by":"crossref","first-page":"11188","DOI":"10.1002\/jcp.27768","article-title":"Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit","volume":"234","author":"Bertacchini","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jbior.2023.100974_bib4","article-title":"Signaling pathways and regulation of gene expression in hematopoietic cells","volume":"88","author":"Bogush","year":"2022","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2023.100974_bib5","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/cells10112833","article-title":"A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia","volume":"10","author":"Bolandi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jbior.2023.100974_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3324\/haematol.2017.165159","article-title":"Acute myeloid leukemia including favorable-risk group samples engraft in NSG mice: just be patient","volume":"102","author":"Bonnet","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jbior.2023.100974_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2023.100974_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118731","article-title":"Deregulated PTEN\/PI3K\/AKT\/mTOR signaling in prostate cancer: still a potential druggable target?","volume":"1867","author":"Braglia","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.jbior.2023.100974_bib9","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.3390\/ijms22136857","article-title":"The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities","volume":"22","author":"Bruno","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbior.2023.100974_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/gcc.22805","article-title":"The cell of origin and the leukemia stem cell in acute myeloid leukemia","volume":"58","author":"Chopra","year":"2019","journal-title":"Gene Chromosome Cancer"},{"key":"10.1016\/j.jbior.2023.100974_bib11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2023.100974_bib12","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML: rationale and clinical evidence","volume":"9","author":"Darici","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jbior.2023.100974_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2021.100830","article-title":"Synergistic cytotoxicity of dual PI3K\/mTOR and FLT3 inhibition in FLT3-ITD AML cells","volume":"82","author":"Darici","year":"2021","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2023.100974_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML:review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2023.100974_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbior.2023.100974_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2023.100955","article-title":"Advances in MDS\/AML and inositide signalling","volume":"87","author":"De Stefano","year":"2023","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2023.100974_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118635","article-title":"Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer","volume":"1867","author":"Evangelisti","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.jbior.2023.100974_bib18","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3390\/cells10112992","article-title":"Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance","volume":"10","author":"Fleischmann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jbior.2023.100974_bib19","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/ijms21238975","article-title":"NPM1-Mutated myeloid neoplasms with <20% blasts: a really distinct clinico-pathologic entity?","volume":"21","author":"Forghieri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbior.2023.100974_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.jbior.2023.100974_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5966\/sctm.2013-0166","article-title":"A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms","volume":"3","author":"Griessinger","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jbior.2023.100974_bib22","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-15-2063","article-title":"Frequency and dynamics of leukemia-initiating cells during short-term ex vivo culture informs outcomes in acute myeloid leukemia patients","volume":"76","author":"Griessinger","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2023.100974_bib23","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/ijms20225792","article-title":"PI3K\/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases","volume":"20","author":"Hillmann","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbior.2023.100974_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782065","article-title":"LY294002 is a promising inhibitor to overcome sorafenib resistance in FLT3-ITD mutant AML cells by interfering with PI3K\/akt signaling pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbior.2023.100974_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbior.2023.100974_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hon.3076","article-title":"DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: implications for clonal evolution and disease progression","volume":"41","author":"Lagunas-Rangel","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.jbior.2023.100974_bib27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2023.100974_bib28","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jbior.2023.100974_bib29","first-page":"12","article-title":"Acute myeloid leukemia: novel mutations and their clinical implications","volume":"13","author":"Makkar","year":"2023","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jbior.2023.100974_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-03738-0","article-title":"A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival","volume":"12","author":"Massett","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbior.2023.100974_bib31","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.18632\/oncotarget.6315","article-title":"Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K\/Akt\/mTOR signaling","volume":"7","author":"Mediani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2023.100974_bib32","first-page":"1911","article-title":"Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2023.100974_bib33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jbior.2018.09.012","article-title":"IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update","volume":"71","author":"Oliveira","year":"2019","journal-title":"Adv Biol Regul"},{"issue":"11","key":"10.1016\/j.jbior.2023.100974_bib34","article-title":"Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation","volume":"19","author":"Park","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jbior.2023.100974_bib35","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1080\/10428194.2017.1399312","article-title":"The importance of FLT3 mutational analysis in acute myeloid leukemia","volume":"59","author":"Patnaik","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jbior.2023.100974_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41589-020-0596-8","article-title":"Chemical strategies to overcome resistance against targeted anticancer therapeutics","volume":"16","author":"Pisa","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbior.2023.100974_bib37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","article-title":"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis","volume":"93","author":"Port","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jbior.2023.100974_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2023.100974_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2017.03.002","article-title":"Cross-talk between the CK2 and AKT signaling pathways in cancer","volume":"64","author":"Ruzzene","year":"2017","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2023.100974_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jcm5030033","article-title":"Acute myeloid leukemia: a concise review","volume":"5","author":"Saultz","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jbior.2023.100974_bib41","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jbior.2023.100974_bib42","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/leu.2017.13","article-title":"Phosphoproteomic analysis reveals hyperactivation of mTOR\/STAT3 and LCK\/Calcineurin axes in pediatric early T-cell precursor ALL","volume":"31","author":"Serafin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2023.100974_bib43","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2023.100974_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbior.2014.04.001","article-title":"Signaling specificity in the akt pathway in biology and disease","volume":"55","author":"Toker","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2023.100974_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biomaterials.2017.02.015","article-title":"Essential design considerations for the resazurin reduction assay to noninvasively quantify cell expansion within perfused extracellular matrix scaffolds","volume":"129","author":"Uzarski","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jbior.2023.100974_bib46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2023.100974_bib49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2023.100974_bib47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-017-0003-y","article-title":"Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML","volume":"32","author":"Zampini","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2023.100974_bib48","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","article-title":"Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment","volume":"120","author":"Zeng","year":"2012","journal-title":"Blood"}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492623000209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492623000209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:28:25Z","timestamp":1761949705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492623000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":49,"alternative-id":["S2212492623000209"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2023.100974","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2023.100974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Universit\u00e0 degli Studi di Modena e Reggio Emilia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100974"}}